After building a rep as an architect of experiments, RxCelerate plants its flag in America
When XO1 was bought out by J&J a couple of years ago, the seed investors at Index, now Medicxi, made it Exhibit A for their business model on creating a portfolio of asset-based biotechs.
What started off with a bit of scientific sleuthing by a pair of researchers at Cambridge University — Trevor Baglin and Jim Huntington — led to an antibody program for a drug dubbed ichorcumab that promised to potentially act as an anticoagulant, without the inherent risk of severe bleeding that inevitably haunts the class.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.